A mucin isoform-based biomarker assay to improve follow-up and treatment of inflammatory bowel diseases (IBD) and gastrointestinal (GI) cancers. University of Antwerp
Inflammatory bowel diseases (IBD), colorectal cancer (CRC) and gastric cancer (GC), still remain disease entities with a high morbidity burden and are major contributors to health problems worldwide. The burden of IBD is rising globally with substantial variation in levels and trends of disease. Most available therapies with biologicals are directed against the inflammatory responses, but still a substantial number of patients fail to respond or ...